Johnson & Johnson (NYSE:JNJ) Shares Acquired by Birch Capital Management LLC

Posted by Defense World Staff on May 4th, 2023

Birch Capital Management LLC raised its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 1.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 18,916 shares of the company’s stock after acquiring an additional 348 shares during the period. Johnson & Johnson makes up 2.3% of Birch Capital Management LLC’s holdings, making the stock its 15th biggest holding. Birch Capital Management LLC’s holdings in Johnson & Johnson were worth $3,342,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also made changes to their positions in JNJ. Glassy Mountain Advisors Inc. acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $35,000. Retirement Financial Solutions LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $40,000. TD Capital Management LLC acquired a new position in shares of Johnson & Johnson in the third quarter valued at approximately $48,000. VitalStone Financial LLC acquired a new position in shares of Johnson & Johnson in the fourth quarter valued at approximately $52,000. Finally, Iron Horse Wealth Management LLC grew its holdings in shares of Johnson & Johnson by 112.8% in the fourth quarter. Iron Horse Wealth Management LLC now owns 300 shares of the company’s stock valued at $53,000 after purchasing an additional 159 shares in the last quarter. 67.94% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Johnson & Johnson

In related news, insider James D. Swanson sold 1,062 shares of the company’s stock in a transaction on Monday, March 6th. The shares were sold at an average price of $154.66, for a total value of $164,248.92. Following the completion of the sale, the insider now owns 9,215 shares in the company, valued at approximately $1,425,191.90. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 0.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

JNJ has been the subject of a number of research reports. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price objective on shares of Johnson & Johnson in a report on Wednesday, February 1st. Atlantic Securities dropped their price objective on shares of Johnson & Johnson from $168.00 to $167.00 and set a “neutral” rating for the company in a report on Wednesday, April 19th. StockNews.com initiated coverage on shares of Johnson & Johnson in a report on Thursday, March 16th. They issued a “strong-buy” rating for the company. UBS Group assumed coverage on shares of Johnson & Johnson in a report on Tuesday, March 28th. They issued a “neutral” rating and a $164.00 price objective for the company. Finally, SVB Leerink decreased their price target on shares of Johnson & Johnson from $194.00 to $186.00 and set an “outperform” rating for the company in a research note on Friday, January 20th. Seven research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $173.00.

Johnson & Johnson Stock Down 1.3 %

Shares of NYSE:JNJ opened at $162.87 on Thursday. The company has a market capitalization of $424.16 billion, a PE ratio of 34.07, a P/E/G ratio of 2.78 and a beta of 0.53. The company has a current ratio of 0.99, a quick ratio of 0.77 and a debt-to-equity ratio of 0.35. Johnson & Johnson has a twelve month low of $150.11 and a twelve month high of $183.35. The firm has a 50 day simple moving average of $158.10 and a 200-day simple moving average of $167.02.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, April 18th. The company reported $2.68 earnings per share for the quarter, topping the consensus estimate of $2.51 by $0.17. The business had revenue of $24.75 billion during the quarter, compared to the consensus estimate of $23.61 billion. Johnson & Johnson had a net margin of 13.22% and a return on equity of 35.53%. The company’s revenue was up 5.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.67 EPS. On average, equities analysts predict that Johnson & Johnson will post 10.66 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 6th. Investors of record on Tuesday, May 23rd will be given a $1.19 dividend. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.13. The ex-dividend date is Monday, May 22nd. This represents a $4.76 annualized dividend and a yield of 2.92%. Johnson & Johnson’s dividend payout ratio is 94.56%.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and MedTech. The Consumer Health segment includes products focused on personal healthcare used in the Skin Health/Beauty, Over-the-Counter medicines, Baby Care, Oral Care, Women’s Health and Wound Care markets.